Aspirin Use and Prostate Cancer among African American Men in the Southern Community Cohort Study

Abstract

Background:

The association of aspirin use with prostate cancer has been investigated but few studies included African American men. Here, we analyzed the relationship of aspirin intake with prostate cancer risk and mortality among African American men in the Southern Community Cohort Study (SCCS).

Methods:

SCCS recruited 22,426 African American men between 2002 and 2009. Aspirin use was assessed at enrollment. Our exposures of interest were any aspirin use (regular strength, low-dose or baby aspirin, or half tablets of aspirin) and regular strength aspirin. Each exposure variable was compared with non-users. Associations between aspirin use and prostate cancer risk and mortality were examined with Cox proportional hazards models.

Results:

At enrollment, 5486 men (25.1%) reported taking any aspirin and 2634 men (12.1%) reported regular strength aspirin use. During follow-up (median 13 years), 1058 men developed prostate cancer including 103 prostate cancer-specific deaths. Aspirin use was not associated with prostate cancer development [adjusted hazard ratio (HR) = 1.07, 95% confidence interval: 0.92 – 1.25 for any aspirin use, HR = 0.97, 0.78 – 1.19 for regular strength aspirin], but was suggestively associated with a reduced prostate cancer mortality (HR = 0.66, 0.39 – 1.14 for any aspirin use, HR = 0.41, 0.17 – 1.00 for regular strength aspirin).

Conclusions:

Aspirin use at enrollment was tentatively associated with a reduced prostate cancer mortality but not risk among African American men in SCCS.

Impact:

Prospective SCCS data suggest that aspirin use may help prevent lethal prostate cancer among this high-risk group of men.

Introduction

Men of African ancestry have an excess risk of developing and dying from prostate cancer (1–6). We have had limited success in reducing this health disparity. Our group and others previously described an immune-inflammation signature that is prevalent in prostate tumors of African American men but absent in most European American men (7–12). This gene signature associated with an increased risk of recurrent disease (11), suggesting that potential inhibitors of this inflammation-related signature, such as an anti-inflammatory drug like aspirin, may prevent prostate cancer progression in African American men. In agreement with the hypothesis, we reported that aspirin use at time of disease diagnosis was associated with fewer cases having advanced stage prostate cancer and a lower risk of disease recurrence among African American men in the NCI-Maryland Prostate Cancer Case-Control Study (13). There have been numerous studies investigating the association of regular aspirin intake with prostate cancer risk (14–17) and disease mortality and survival (18–21) among European American men, with several reporting an association with reduced mortality, but few studies have included African American men. Here, we pursued the hypothesis that use of aspirin prior to a disease diagnosis reduces prostate cancer risk and mortality among African American men in the Southern Community Cohort Study (SCCS), a large cohort study that prospectively recruited low-income and predominately African American participants to investigate the causes of cancer health disparities (22).

Materials and Methods

Southern Community Cohort Study.

SCCS focused on the recruitment of a low-income, predominantly African American population from a 12 state area of the Southeast (22). Accordingly, 59% of the recruited African American men came from households with less than $15,000 of annual household income and 21% from households with annual incomes between $15,000 and $25,000 at time of recruitment (23). Recruitment began in March 2002 and was completed in September 2009. Informed consent was obtained from all study participants, and the study was approved by the Institutional Review Boards of the involved institutions. Participants were asked to complete an in-person interview at enrollment. About 85,000 men and women aged 40 to 79 were recruited into this study. To obtain follow up data on cancer development, procedures for data linkage, processing, and quality control were established with the 12-state cancer registries covering the SCCS catchment area (Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia). These registries provide the primary source of identifying incident cancer diagnoses and disease characteristics. Information on disease staging followed the 7th edition of the American Joint Committee on Cancer (AJCC) TNM system for clinical stage, abbreviated as I – IV. We defined aggressive prostate cancer as Stage IV (T4) or N1 or M1 by AJCC, or Gleason score ≥ 8 (high grade), as previously described (24). Cohort member deaths were identified through annual linkages with both the Social Security Administration and the National Death Index (NDI). For the current study, SCCS state cancer registries reporting was completed through 12/31/2016 and NDI reporting through 12/31/2018. We examined the SCCS dataset for all self-reported African American men (n = 22,426). Of these men, 1058 developed prostate cancer. During the study follow-up (median 13 years, maximum 16.8 years), a total of 6627 deaths occurred including 103 prostate cancer-related deaths as defined by International Classification of Diseases 10^th criteria using NDI data. All participants provided written informed consent for the studies that were conducted. The research followed the ethical guidelines set by the Declaration of Helsinki.

Assessment of aspirin use.

We pursued two exposures of interests, any aspirin use and regular strength aspirin use. The SCCS baseline survey evaluated aspirin use with the following questions: (i) In the past year, have you taken the following medication regularly? By regularly, we mean at least two times per week for one month or more: Regular aspirin (such as Anacin, Bayer, Bufferin, Excedrin, etc.) with No or Yes; low-dose aspirin, baby aspirin, or half tablets of aspirin with No or Yes. (ii) How many years have you taken this type of medication regularly. # years was calculated. (iii) When you took this regularly, what is the average number of pills you took per week? # pills was calculated. 97.4% of the participants (21,851 out of 22,426) answered the questions on aspirin use at enrollment. We created aspirin use categories based on question (i). The use of regular aspirin was defined as “regular-strength aspirin use” in the study, whereas “any aspirin use” was defined as taking either regular aspirin, low-dose or baby aspirin, or half tablets of aspirin. Use was then categorized as either “no” or “yes”. For all analyses, non-users of aspirin were men who did not report any aspirin use. The aspirin category was further categorized as either “taken more than 7 pills per week” or “taken 7 pills per week or less” based on question (iii). Duration of aspirin use was based on question (ii). Duration was then categorized as either “less than or equal to 3 years”, or “more than 3 years”, as done previously (13).

Statistical analysis.

Cox proportional hazards regression models with age as the time scale were used to calculate hazard ratios (HR) for disease risk and disease-specific mortality. Our exposures of interest were any aspirin use and regular strength aspirin. Each exposure variable was separately compared with non-users. Models to assess disease risk and mortality contained the same covariates [age, year of enrollment (categorical), education (without high school degree, high school degree, college degree, graduate degree), household income (<$15,000, $15,000–25,000, >$25,000–50,000, >$50,000–100,000, >$100,000), family history of prostate cancer including father and brother (yes/no), smoking status (current, former, never), diabetes (yes/no), body mass index (BMI, as six categories <18.5, 18.5–25, 25–30, 30–35, 35–40, >40 kg/m²), benign prostate hyperplasia (BPH) (yes/no), prostate cancer screening by PSA test (yes/no) and digital rectal exam (DRE) (yes/no), acetaminophen (yes/no) and other non-steroidal anti-inflammatory drug (NSAID) use (yes/no)]. In the analysis of disease risk, men contributed follow-up time from enrollment until incident cancer, death or last follow-up. We performed additional secondary analyses after grouping patients by disease stage (TNM I/II versus III/IV), by Gleason score [≤ 7 (low/medium grade) versus ≥ 8 (high grade)], and by disease aggressiveness (T4 or N1 or M1 or Gleason score ≥8). In these stratified analyses, the other cases were removed (e.g., when data for early stage disease were analyzed, cases with late stage disease were removed). Models were adjusted for potential confounders, as aforementioned. Individuals who did not answer the aspirin survey questions or with missing values for the two exposure variables were excluded from the analysis. Missing data for covariates were imputed as mean values. Because PSA levels were measured in a subset of men at baseline, we compared these PSA levels between aspirin users and non-users to evaluate an aspirin effect.

In the mortality analysis, we compared the risk of fatal prostate cancer by aspirin use among men without prostate cancer at enrollment. Men contributed follow-up time from enrollment until death or last follow-up at 12/31/2018. Deaths from causes other than prostate cancer were censored. Subdistribution hazard ratios were calculated using Fine and Grey regression to examine the impact of aspirin use on the cumulative probability of prostate cancer death in the presence of competing events.

Tests for trend related to frequency and duration of aspirin use were performed by calculating P values in regression models with aspirin use coded as an ordinal variable. Data analysis was performed using the R statistical software, version 3.6.0. All statistical tests were two-sided. An association was considered statistically significant with P < 0.05.

Results

Demographics and clinicopathological features.

The study recruited 22,426 African American men of whom 1058 developed prostate cancer on follow up. At enrollment, 5486 men (25.1%) reported taking any aspirin and 2634 men (12.1%) reported taking regular strength aspirin. Characteristics of the African American men by aspirin use are shown in Table 1. The median age at enrollment was 49 (IQR = 11) years, with a median follow-up time of 13 years. Baseline characteristics of men who used or did not use aspirin differed significantly with respect to age, education, and smoking status (Table 1). Aspirin users were more likely to have an elevated BMI (28.5 vs. 26.1 for any aspirin; 28.1 vs. 26.1 for regular strength aspirin), a history of diabetes (33.8% vs. 12.9% for any aspirin; 27.5% vs. 12.9% for regular strength aspirin), BPH (9.4% vs. 3.8% for any aspirin; 7.2% vs. 3.8% for regular strength aspirin), or family history of prostate cancer (6.0% vs. 4.3% for any aspirin; 5.9% vs. 4.3%). Among men who were diagnosed with prostate cancer, 120 (11.3%) with disease stage information presented with an advanced stage disease (TNM III/IV) and 169 (16.0%) with an aggressive disease (T4 or N1 or M1 or Gleason score ≥ 8).

Table 1 -.

Baseline characteristics of African American men in the SCCS study by aspirin use

	No Aspirin		Any Aspirin		Regular strength Aspirin
	(n)	(%)	(n)	(%)	(n)	(%)
Total	16365	74.9a	5486	25.1	2634	12.1
Age median (IQR)	48 (10)		53 (13)		52 (12)
BMI median (IQR)	26.1 (7)		28.5 (7.8)		28.1 (7.8)
Education
Less High	5526	33.8b	1823	33.2	913	34.7
High school	6903	42.2	2028	37.0	991	37.6
College	2751	16.8	992	18.1	471	17.9
More than College	1085	6.6	548	10.0	227	8.6
Household income
< 15k	10138	61.9	2900	52.9	1477	56.1
15K-25K	3453	21.1	1176	21.4	539	20.5
25K-50	1840	11.2	855	15.6	386	14.7
50K-100K	620	3.8	381	6.9	156	5.9
> 100k	153	0.9	113	2.1	38	1.4
Family history of prostate cancer
No	15606	95.4	5123	93.4	2460	93.4
Yes	703	4.3	331	6.0	156	5.9
Tobacco use
Current	10017	61.2	2457	44.8	1343	51.0
Former	2814	17.2	1640	29.9	701	26.6
Never	3475	21.2	1335	24.3	559	21.2
Diabetes
No	14242	87.0	3629	66.2	1906	72.4
Yes	2112	12.9	1853	33.8	725	27.5
BPH
No	15689	95.9	4936	90.0	2432	92.3
Yes	627	3.8	516	9.4	189	7.2
PSA screening
No	9076	55.5	2067	37.7	1180	44.8
Yes	6402	39.1	3109	56.7	1299	49.3
DRE screening
No	7611	46.5	1760	32.1	978	37.1
Yes	8666	53.0	3681	67.1	1636	62.1

Abbreviations: IQR, interquartile range; BMI, body mass index; BPH, benign prostate hyperplasia; PSA, prostate cancer-specific antigen; DRE, digital rectal examination

^apercent of all men in study (n = 21851);

^bpercent of men within aspirin group [no aspirin (n = 16365), any aspirin (n = 5486), regular strength aspirin (n = 2634)] for all listed variables. Missing data not included in percentages

Aspirin use and prostate cancer risk.

In the multivariable-adjusted Cox regression analysis, aspirin use at enrollment was not associated with prostate cancer risk (HR = 1.07, 95% confidence interval: 0.92 – 1.25 for any aspirin use, HR = 0.97, 0.78 – 1.19 for regular strength aspirin, Table 2). Associations remained null when examined by frequency of use (HR = 1.03, 0.77–1.39 for less than daily use, HR = 1.07, 0.91–1.26 for daily use, P trend =0.41) and duration of use (HR = 1.07, 0.89–1.28 for ≤ 3 years of use, HR = 1.05, 0.84–1.30 for >3 years of use, P trend =0.45). No significant association was observed between any aspirin use and risk of advanced stage, high grade or aggressive disease. Only use of regular strength aspirin showed a suggestive association with a reduced risk of advanced stage disease (HR = 0.70, 0.34–1.41), but this association was not statistically significant.

Table 2 –

Associations between aspirin use at enrollment and prostate cancer risk among African American men in SCCS

	Events	PY	HR (95% CI)a	P value	HR (95% CI)b	P value
Overall
No use	690	162857	ref.		ref.
Any use	332	50057	1.11 (0.97–1.27)	0.14	1.07 (0.92–1.25)	0.40
Regular strength	136	25091	1.01 (0.84–1.21)	0.95	0.97 (0.78–1.19)	0.75
Less than daily	54	10934	1.00 (0.75–1.32)	0.97	1.03 (0.77–1.39)	0.84
Daily and more	269	37850	1.13 (0.98–1.31)	0.09	1.07 (0.91–1.26)	0.42
					P trend	0.41
≤3 years	189	30283	1.09 (0.92–1.28)	0.31	1.07 (0.89–1.28)	0.48
>3 years	135	18417	1.12 (0.93–1.36)	0.24	1.05 (0.84–1.30)	0.68
					P trend	0.45
TNM stage I/II
No use	420	162857	ref.		ref.
Any use	214	50057	1.12 (0.94–1.32)	0.21	1.03 (0.85–1.26)	0.74
Regular strength	90	25091	1.06 (0.84–1.34)	0.61	0.98 (0.75–1.28)	0.88
TNM stage III/IV
No use	90	162857	ref.		ref.
Any use	30	50057	0.83 (0.54–1.28)	0.40	1.00 (0.63–1.60)	0.98
Regular strength	9	25091	0.54 (0.27–1.07)	0.08	0.70 (0.34–1.41)	0.31
Gleason ≤ 7
No use	404	162857	ref.		ref.
Any use	181	50057	1.08 (0.90–1.29)	0.41	0.95 (0.77–1.17)	0.64
Regular strength	76	25091	0.98 (0.77–1.26)	0.88	0.90 (0.68–1.20)	0.48
Gleason ≥ 8
No use	86	162857
Any use	44	50057	1.15 (0.79–1.68)	0.46	1.36 (0.89–2.08)	0.15
Regular strength	16	25091	0.93 (0.54–1.59)	0.78	0.95 (0.51–1.75)	0.87
Aggressivec
No use	116	162857	ref.		ref.
Any use	53	50057	1.04 (0.74–1.46)	0.80	1.17 (0.80–1.71)	0.42
Regular strength	19	25091	0.82 (0.51–1.34)	0.44	0.84 (0.49–1.46)	0.54

Abbreviations: PY, person-years; HR, hazard ratio; CI, confidence interval; TNM, tumor-node-metastasis

^aHR was adjusted for age

^bHR was adjusted for age, enrollment year, education, income, family history of prostate cancer, smoking status, diabetes, BMI, BPH, PSA and DRE screening, acetaminophen, NSAIDs other than aspirin

^cT4 or N1 or M1 or Gleason score ≥ 8

Aspirin use and disease-specific mortality.

In this analysis, we assessed the risk of fatal prostate cancer related to baseline aspirin use among men without prostate cancer. During follow-up, 103 men developed fatal prostate cancer. In the multivariable-adjusted Cox regression analysis, aspirin use at enrollment tentatively associated with a reduced prostate cancer mortality (HR = 0.66, 0.39 to 1.14 for any aspirin use; HR = 0.41, 0.17 to 1:00 for regular strength aspirin use, Table 3). There was not much of an influence of competing risks of death on the risk of fatal prostate cancer, as shown by the sub-distribution HRs (SHRs) in the Fine-Gray competing risk regression model (Table 3).

Table 3 –

Association between aspirin use at enrollment and prostate cancer mortality among African American men in SCCS

	Events	PY	HR (95% CI)a	P	HR (95% CI)b	P	SHR (95% CI)	P
No aspirin use	74	2368439	ref.		ref.		ref.
Any aspirin usec	25	744964	0.65 (0.41–1.03)	0.07	0.66 (0.39–1.14)	0.14	0.69 (0.39–1.25)	0.22
Regular strength	6	369317	0.36 (0.16–0.84)	0.02	0.41 (0.17–1.00)	0.05	0.43 (0.16–1.13)	0.09

Abbreviations: PY, person-years; HR, hazard ratio; CI, confidence interval; SHR, sub-distribution hazard ratio

^aHR was adjusted for age

^bHR was adjusted for age, enrollment year, education, income, family history of prostate cancer, smoking status, diabetes, BMI, BPH, PSA and DRE screening, acetaminophen, NSAIDs other than aspirin

^cany aspirin use category also includes regular strength events

Discussion

Men of African ancestry are a high-risk population for prostate cancer and have an excess risk of developing lethal disease (1,2,25,26). Using the NCI-Maryland Prostate Cancer Case-Control Study, we previously reported that intake of aspirin at diagnosis was inversely associated with advanced stage prostate cancer and disease recurrence among these men (13). Here, we extended this study and examined the relationship between self-reported aspirin use at enrollment into SCCS and prostate cancer risk and mortality among African American men. We did not observe an association between aspirin use and prostate cancer risk, but aspirin use tended to be associated with a lower prostate cancer mortality. Our observations are plausible as recent mechanistic observations and epidemiologic data showed that aspirin could have promising effects on reducing metastasis and cancer mortality (27,28).

This is the first study that specifically investigated the relationship between aspirin use and prostate cancer mortality among African American men using a prospective design. SCCS recruited both African American and European American men from a predominantly low-income background. Because only 22 of the European American men progressed into fatal prostate cancer (versus 103 African American men), we did not examine the relationship of aspirin use with prostate cancer mortality among these men. There have been previous reports showing that regular aspirin intake may reduce the risk of prostate cancer (14–17) although a robust protective relationship may only exist with the aggressive disease (29–31) and disease mortality and survival (18–20). Nonetheless, data for men of African ancestry remain sparse. Hurwitz et al. investigated the relationship of aspirin use with prostate cancer in the Atherosclerosis Risk in Communities Study, a prospective study that included 5060 European American men and 1534 African American men (19). In this cohort, aspirin use was inversely associated with prostate cancer mortality, but did not associate with disease incidence, which is consistent with our findings in SCCS. An additional race-stratified analysis – although limited by the relative low number of African American men who participated in this study – showed a suggestive protective effect of aspirin against prostate cancer mortality among the African American men (adjusted HR 0.41; 95% CI 0.14–1.20). This observation is again consistent with our findings in the current study.

Aspirin may protect against lethal prostate cancer among African American men by suppressing an immune-inflammation signature in their cancerous prostate (7,11,12), as we hypothesize. Aspirin may also exert a more general protection by suppressing metastasis (32). Treating prostate cancer patients with celecoxib, a selective cyclooxygenase-2 (COX2) inhibitor, did not confer a survival benefit in the STAMPEDE trial (33). Aspirin is thought to have cancer preventive activity by inhibiting the same pathway and the production of prostaglandins. Yet, in contrast to COX2-specific inhibitors, aspirin irreversibly inhibits both COX1 & 2 activity by acetylation. Acetylation of COX1, which is the main enzyme activity in platelets, blocks the production of thromboxane A2. It has now been shown in an animal model of lung metastasis that aspirin inhibits the metastatic spread by blocking the formation of a metastatic intravascular niche that depends on platelet-derived thromboxane A2 (27), although comparable data for prostate cancer and bone metastasis are still missing. Still, such a mechanism would explain why aspirin may inhibit lethal prostate cancer more so than the localized disease, as observed in our study and the study by Hurwitz et al. (19). In addition to its ability to inhibit prostaglandin synthesis, aspirin can turn on the production of anti-inflammatory lipid mediators, lipoxins, which makes aspirin further distinct in function from other NSAIDs (34,35). Lastly, aspirin has additional anti-inflammatory actions that cannot be attributed to its ability to inhibit prostaglandin biosynthesis, such as blocking leukocyte trafficking to inflamed tissues. As such, aspirin may have unique cancer preventive activities and may distinctly inhibit metastasis and lethal cancer.

Aspirin is commonly used in the US population, which is primarily for prevention of cardiovascular disease. Its usage increases among the elderly (36). A recent survey reported an estimated use of about 50% among U.S. adults aged 45–75 years (37). The observation indicates that aspirin use can be under-reported when enrollment data are used. Aspirin effects in cancer prevention have been linked to dosage and duration although a dosage or duration effect for the relationship of aspirin use with the risk of lethal prostate cancer remains to be determined (18–20). We stratified aspirin into any aspirin and regular strength aspirin use but could not stratify further because of inadequate statistical power. Regular strength aspirin is usually a 325 mg dose of aspirin (38) whereas our any aspirin use group comprised additional users of low-dose aspirin (about 50%). Accordingly, we found that the inverse relationship of aspirin use with prostate cancer mortality is somewhat stronger among regular strength aspirin than any aspirin users, consistent with a dose effect, however, the confidence intervals largely overlapped and there was no significant difference between the two groups.

There are several limitations to our study. Firstly, we did not assess the exact daily dose of aspirin beyond the number of tablets per day. Also, we did not collect information on the reasons why participants were taking aspirin, however, most aspirin use is for prevention of cardiovascular disease among the elderly in the U.S. and follows recommendations by primary care physicians (37). Secondly, we did not receive information on disease characteristics for all men with prostate cancer. Accordingly, we had missing data on disease stage and Gleason score for 25–30% of the patients, limiting our ability to analyze the relationship between aspirin use and advanced disease in this study. Thirdly, studies reported that aspirin leads to lower blood PSA, leading to a potential under-estimate of disease occurrence among aspirin users in the prostate cancer risk analysis (39). We observed a rather modest effect of aspirin use on PSA levels in SCCS with a median PSA reduction of 9.1% among all men who were regular strength aspirin users and only a 2.5% reduction among men who were aspirin users at baseline and later developed prostate cancer (Supplementary Figure 1). Fourthly, to abrogate a possible confounding effect of access to healthcare on the relationship between aspirin use and prostate cancer mortality, we adjusted a series of factors, such as age, socioeconomic status (education and income), smoking status, medical history of diabetes, BMI, BPH, acetaminophen and other NSAID use, and PSA and DRE screening in the multivariable Cox regression model. In our mortality analysis we cannot adjust for received prostate cancer therapy. However, other studies have reported rather modest differences in obtained primary prostate cancer treatment comparing aspirin users with non-users (40) and our adjustments for socioeconomic status and PSA screening should capture differences in primary care and treatment if they exist. Nevertheless, we cannot exclude residual confounding as an underlying factor for our observations. We could not adjust for cardiovascular risk factors or some medications as these data were not collected in SCCS. Lastly, the mortality analysis was limited by a small number of events, which may have prevented us to observe a more definite relationship between aspirin use and a reduced prostate cancer mortality. Additional studies are needed to replicate and strengthen our findings.

Conclusions

Self-reported aspirin use associated with a decreased prostate cancer-specific mortality among African American men in SCCS. Yet, uncertainty remains about the strength of this association. In contrast, our data did not indicate an association between aspirin use and the risk of developing the disease. Our observations suggest that aspirin for prevention should be further evaluated as an opportunity to decrease lethal prostate cancer in these men.

Abbreviations:

SCCS

Southern Community Cohort Study

HR

hazard ratio

OR

odds ratio

CI

confidence interval

PSA

prostate-specific antigen

BMI

body mass index

BPH

benign prostate hyperplasia

NSAID

non-steroidal anti-inflammatory drug